Menü
sharewise sharewise
Einloggen
Registrieren
Einloggen
Registrieren
Microsoft selbst warnt vor der Verwendung von Internet Explorer, da er nicht mehr den neuesten Web- und Sicherheitsstandards entspricht. Wir können daher nicht garantieren, dass die Seite im Internet Explorer in vollem Umfang funktioniert. Nutze bitte Chrome oder Firefox.

Erstellt von HC Wainwright 

ProQR Therapeutics N.V. diskutieren

ProQR Therapeutics N.V.

WKN: A12B97 / Symbol: PRQR / Name: ProQR / Aktie / Biotechnologie & medizinische Forschung / Small Cap /

?
6,81 %

12 0
12
0
Einschätzung Buy
Rendite (%) 42,67 %
Kursziel 4,39
Veränderung
Endet am 29.04.26

ProQR Therapeutics (NASDAQ: PRQR) is now covered by analysts at Evercore ISI. They set an "outperform" rating and a $5.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat

Evercore ISI 
0
Melden Teilen
29.04.25
Einschätzung Buy
Rendite (%) 42,36 %
Kursziel 8,10
Veränderung
Endet am 13.05.26

ProQR Therapeutics (NASDAQ: PRQR) had its price target lowered by analysts at Oppenheimer Holdings Inc. from $15.00 to $9.00. They now have an "outperform" rating on the stock.
Ratings data for PRQR provided by MarketBeat

Oppenheimer Holdings Inc. 
0
Melden Teilen
13.05.25
Einschätzung Buy
Rendite (%) 6,91 %
Kursziel 6,84
Veränderung
Endet am 27.06.26

ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald. They now have a $8.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat

Cantor Fitzgerald 
0
Melden Teilen
27.06.25
Einschätzung Buy
Rendite (%) 9,34 %
Kursziel 3,43
Veränderung
Endet am 08.08.26

ProQR Therapeutics N.V. (NASDAQ: PRQR) had its "buy" rating re-affirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat

Chardan Capital 
0
Melden Teilen
08.08.25
Einschätzung Buy
Rendite (%) -4,15 %
Kursziel 3,48
Veränderung
Endet am 04.11.26

ProQR Therapeutics (NASDAQ:PRQR) had its "buy" rating reaffirmed by analysts at Chardan Capital. They now have a $4.00 price target on the stock.
Ratings data for PRQR provided by MarketBeat

Chardan Capital 
0
Melden Teilen
04.11.25
Noch kein Mitglied? Jetzt kostenlos registrieren!

Neueste Beiträge

Cowen_Inc in Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "buy" ratin...
11.12.25
Morgan_Stanley in Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its "overweight...
11.12.25
Jefferies_Financial_ in Aerovironment diskutieren
AeroVironment (NASDAQ:AVAV) had its "buy" rating reaffir...
11.12.25
Needham___Company_LL in Rhythm Pharmaceuticals diskutieren
Rhythm Pharmaceuticals (NASDAQ:RYTM) had its price target...
11.12.25
Deutsche_Bank_Aktien in Unilever plc ADR diskutieren
Unilever (NYSE:UL) had its "buy" rating reaffirmed by an...
11.12.25
Deutsche_Bank_Aktien in Compass Minerals Intl. diskutieren
Compass Minerals International (NYSE:CMP) had its price t...
11.12.25
JPMorgan_Chase___Co_ in Brinker International Inc. diskutieren
Brinker International (NYSE:EAT) had its price target rai...
11.12.25
SVB_Leerink_LLC in XOMA Corp. diskutieren
XOMA Royalty (NASDAQ:XOMA) was given a new $45.00 price ...
11.12.25
Mehr anzeigen